# Grifols SA

Summary updated: 2026-10-02T16:44:26.556898Z
Canonical: https://finbar.com/research/companies/grifols-sa

## Overview

Grifols SA is a global healthcare company focused on plasma-derived medicines, alongside in-vitro diagnostic products for clinical and blood-bank laboratories and other hospital products. Its therapies address conditions including immune deficiencies, hemophilia and emphysema. [1](https://app.finbar.com/go?id=P150429086) The company’s stated purpose is to improve health and well-being worldwide. [2](https://www.grifols.com/en/mission-and-values)

Grifols reported FY2025 revenue of €7.524 billion. [3](https://app.finbar.com/go?id=T17227103) Its operations span Europe, the United States, Latin America, Africa and Asia; the company reports more than 25,000 employees, presence in over 30 countries and regions, and products and services reaching more than 110 countries. [4](https://app.finbar.com/go?id=P150429054)[5](https://www.grifols.com/en/company)
[1](https://app.finbar.com/go?id=P150429086)[2](https://www.grifols.com/en/mission-and-values)[3](https://app.finbar.com/go?id=T17227103)[4](https://app.finbar.com/go?id=P150429054)[5](https://www.grifols.com/en/company)[2](https://www.grifols.com/en/mission-and-values)[5](https://www.grifols.com/en/company)

## Products & services

Grifols’ product portfolio includes plasma-derived medicines such as Gamunex/Gamunex-C and Flebogamma 5%/10% DIF, intravenous immunoglobulins used for immunodeficiencies and autoimmune conditions; Xembify, a 20% subcutaneous immune globulin; and Prolastin products, alpha-1 proteinase inhibitors for emphysema associated with severe hereditary alpha-1 antitrypsin deficiency. Its other listed therapies include Factor VIII and von Willebrand factor products for bleeding disorders, albumin solutions at 5%, 20% and 25%, HyperRAB rabies immune globulin, Vistaseal/VeraSeal surgical sealants, and Tavlesse for chronic immune thrombocytopenia. [6](https://app.finbar.com/go?id=T17226542)

For transfusion medicine and blood screening, Grifols offers Procleix Panther systems and nucleic-acid tests to screen donated blood and plasma for infectious agents, and Wadiana, Erytra and Erytra Eflexis automated analyzers for blood typing, antibody testing, phenotyping and crossmatching. Its diagnostic products also include BLOODchip and related Luminex-based multiplex genotyping tests for red-cell and platelet antigens, Promonitor immunoassays to measure biological-drug levels and anti-drug antibodies, and AlphaID cheek-swab genetic screening for alpha-1 deficiency. [7](https://app.finbar.com/go?id=T17226550)

Additional offerings include immunohematology reagents, cards and laboratory software, including Grifols sCD38, designed to address daratumumab interference in pre-transfusion antibody testing, and Blood Typing Manager, which interfaces instruments with laboratory and blood-establishment information systems. Supporting activities include plasma procurement and plasma fractionation and purification; the company also provides diagnostic systems and products for donor–patient compatibility and detection of transfusion-related infections. [8](https://app.finbar.com/go?id=T17226552)[9](https://app.finbar.com/go?id=T17226613)[10](https://app.finbar.com/go?id=T17227436)[11](https://app.finbar.com/go?id=P150429230)
[6](https://app.finbar.com/go?id=T17226542)[7](https://app.finbar.com/go?id=T17226550)[8](https://app.finbar.com/go?id=T17226552)[9](https://app.finbar.com/go?id=T17226613)[10](https://app.finbar.com/go?id=T17227436)[11](https://app.finbar.com/go?id=P150429230)

## Geographic presence

Grifols’ plasma-collection network spans the United States, Europe, Canada and Egypt, where it operates through a joint venture. At year-end 2025, the company reported more than 400 collection centers; Germany, Austria and Hungary are among the European countries specifically identified. [12](https://app.finbar.com/go?id=P150429713)

Its manufacturing, laboratory, research and office footprint includes multiple sites in Spain and the United States, as well as locations in Canada, Ireland, Germany, Switzerland, Australia and Egypt. Dublin serves as the Biopharma global operations and supply-chain center, including global logistics and distribution activities. [9](https://app.finbar.com/go?id=T17226613)[13](https://app.finbar.com/go?id=P150429495) The FY2025 revenue table reports sales by business segment rather than geographic region, so it does not provide a country or regional revenue breakdown. [3](https://app.finbar.com/go?id=T17227103)
[12](https://app.finbar.com/go?id=P150429713)[9](https://app.finbar.com/go?id=T17226613)[13](https://app.finbar.com/go?id=P150429495)[3](https://app.finbar.com/go?id=T17227103)

## Business segments

For FY2025, Grifols reported four revenue segments: Biopharma, Diagnostic, Bio Supplies and Others. Biopharma generated €6,487 million, approximately 86.2% of consolidated revenue of €7,524 million. It focuses on plasma-derived therapeutics, including immunoglobulins, Factor VIII, Alpha 1 and albumin. [3](https://app.finbar.com/go?id=T17227103)[14](https://app.finbar.com/go?id=P150429091)

Diagnostic generated €640 million, approximately 8.5% of revenue, from in-vitro diagnostic products and services, including transfusion medicine and specialty diagnostics. Bio Supplies generated €154 million, approximately 2.0%, supplying human biological materials for research, clinical trials and pharmaceutical or diagnostic manufacturing. Others generated €243 million, approximately 3.2%; the reported materials do not specify a comparable focus area for this segment. Percentages are approximate and may not total 100% due to rounding. [3](https://app.finbar.com/go?id=T17227103)[15](https://app.finbar.com/go?id=P150429094)[16](https://app.finbar.com/go?id=P150429253)[17](https://app.finbar.com/go?id=P150429095)

Grifols also describes Plasma Procurement as a business unit, but excludes it as a reported operating segment: plasma is transferred internally to Biopharma, and the unit generates no external revenue. [18](https://app.finbar.com/go?id=P150429109)
[3](https://app.finbar.com/go?id=T17227103)[3](https://app.finbar.com/go?id=T17227103)[3](https://app.finbar.com/go?id=T17227103)[3](https://app.finbar.com/go?id=T17227103)[3](https://app.finbar.com/go?id=T17227103)[14](https://app.finbar.com/go?id=P150429091)[15](https://app.finbar.com/go?id=P150429094)[16](https://app.finbar.com/go?id=P150429253)[17](https://app.finbar.com/go?id=P150429095)[18](https://app.finbar.com/go?id=P150429109)

## Company history

Grifols traces its origins to a clinical-analysis laboratory established in Barcelona in 1909 by Josep Antoni Grifols i Roig. The company was founded in 1940, when he and his sons Josep Antoni and Víctor Grifols i Lucas established Laboratorios Grifols. In 1943 it patented a lyophilization process in Spain, and in 1945 opened Hemobanco, described by the company as Spain’s first private blood and plasma bank. [19](https://grifols.com/en/our-history)

Grupo Grifols was formed in 1987, and its Parets del Vallès facilities received their first U.S. FDA license in 1995. The company expanded its diagnostics business through the acquisition of ATC assets in 2003. [20](https://www.grifols.com/en/grifols-museum-the-world-from-family-business-to-global-company) [21](https://www.grifols.com/documents/3627767/3632471/np-20131111-en.pdf) In 2010 Grifols agreed to acquire Talecris, completing the acquisition in 2011 and substantially expanding its plasma-derived therapies business. [22](https://www.grifols.com/documents/3627767/3632474/13_np_07062010_acquire%2Btalecris_therapies_en.pdf) [23](https://www.grifols.com/documents/3627767/3632468/05_np_28072011_increase_30_2_en.pdf)

Grifols took a significant minority stake in Alkahest in 2015 and acquired the company in full in 2020. [24](https://app.finbar.com/go?id=P150429073) In 2022 it acquired Biotest Holdings, gaining a majority stake in Biotest and access to additional plasma-collection centers. [25](https://app.finbar.com/go?id=P150429071) [26](https://app.finbar.com/go?id=P150429072) Leadership transitions included Víctor Grifols Deu and Raimon Grifols Roura serving as joint CEOs from 2017 until May 2023, followed by José Ignacio Abia becoming CEO in 2024. [27](https://app.finbar.com/go?id=P150430133) [28](https://app.finbar.com/go?id=P150430136)
[19](https://grifols.com/en/our-history)[20](https://www.grifols.com/en/grifols-museum-the-world-from-family-business-to-global-company)[21](https://www.grifols.com/documents/3627767/3632471/np-20131111-en.pdf)[22](https://www.grifols.com/documents/3627767/3632474/13_np_07062010_acquire%2Btalecris_therapies_en.pdf)[23](https://www.grifols.com/documents/3627767/3632468/05_np_28072011_increase_30_2_en.pdf)[24](https://app.finbar.com/go?id=P150429073)[25](https://app.finbar.com/go?id=P150429071)[26](https://app.finbar.com/go?id=P150429072)[27](https://app.finbar.com/go?id=P150430133)[28](https://app.finbar.com/go?id=P150430136)[19](https://grifols.com/en/our-history)[20](https://www.grifols.com/en/grifols-museum-the-world-from-family-business-to-global-company)[21](https://www.grifols.com/documents/3627767/3632471/np-20131111-en.pdf)[22](https://www.grifols.com/documents/3627767/3632474/13_np_07062010_acquire%2Btalecris_therapies_en.pdf)[23](https://www.grifols.com/documents/3627767/3632468/05_np_28072011_increase_30_2_en.pdf)

## Sources

1. [Grifols SA — Full financial report (2025 Y)](https://app.finbar.com/go?id=P150429086)
2. [www.grifols.com](https://www.grifols.com/en/mission-and-values)
3. [Grifols SA — Full financial report (2025 Y)](https://app.finbar.com/go?id=T17227103)
4. [Grifols SA — Full financial report (2025 Y)](https://app.finbar.com/go?id=P150429054)
5. [www.grifols.com](https://www.grifols.com/en/company)
6. [Grifols SA — Full financial report (2025 Y)](https://app.finbar.com/go?id=T17226542)
7. [Grifols SA — Full financial report (2025 Y)](https://app.finbar.com/go?id=T17226550)
8. [Grifols SA — Full financial report (2025 Y)](https://app.finbar.com/go?id=T17226552)
9. [Grifols SA — Full financial report (2025 Y)](https://app.finbar.com/go?id=T17226613)
10. [Grifols SA — Full financial report (2025 Y)](https://app.finbar.com/go?id=T17227436)
11. [Grifols SA — Full financial report (2025 Y)](https://app.finbar.com/go?id=P150429230)
12. [Grifols SA — Full financial report (2025 Y)](https://app.finbar.com/go?id=P150429713)
13. [Grifols SA — Full financial report (2025 Y)](https://app.finbar.com/go?id=P150429495)
14. [Grifols SA — Full financial report (2025 Y)](https://app.finbar.com/go?id=P150429091)
15. [Grifols SA — Full financial report (2025 Y)](https://app.finbar.com/go?id=P150429094)
16. [Grifols SA — Full financial report (2025 Y)](https://app.finbar.com/go?id=P150429253)
17. [Grifols SA — Full financial report (2025 Y)](https://app.finbar.com/go?id=P150429095)
18. [Grifols SA — Full financial report (2025 Y)](https://app.finbar.com/go?id=P150429109)
19. [grifols.com](https://grifols.com/en/our-history)
20. [www.grifols.com](https://www.grifols.com/en/grifols-museum-the-world-from-family-business-to-global-company)
21. [www.grifols.com](https://www.grifols.com/documents/3627767/3632471/np-20131111-en.pdf)
22. [www.grifols.com](https://www.grifols.com/documents/3627767/3632474/13_np_07062010_acquire%2Btalecris_therapies_en.pdf)
23. [www.grifols.com](https://www.grifols.com/documents/3627767/3632468/05_np_28072011_increase_30_2_en.pdf)
24. [Grifols SA — Full financial report (2025 Y)](https://app.finbar.com/go?id=P150429073)
25. [Grifols SA — Full financial report (2025 Y)](https://app.finbar.com/go?id=P150429071)
26. [Grifols SA — Full financial report (2025 Y)](https://app.finbar.com/go?id=P150429072)
27. [Grifols SA — Full financial report (2025 Y)](https://app.finbar.com/go?id=P150430133)
28. [Grifols SA — Full financial report (2025 Y)](https://app.finbar.com/go?id=P150430136)

AI-generated summary; may contain errors. Not investment advice. Sign up to Finbar to view original document sources and access worldwide fundamental financial data and intelligence.